SML0289
Bromfenac sodium
≥98% (HPLC), COX1 and COX2 inhibitor, powder
동의어(들):
2-Amino-3-(4-bromobenzoyl)benzeneacetic acid sodium salt
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C15H11BrNNaO3
CAS 번호:
Molecular Weight:
356.15
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
제품 이름
Bromfenac sodium, ≥98% (HPLC)
SMILES string
[Na+].Nc1c(CC([O-])=O)cccc1C(=O)c2ccc(Br)cc2
InChI
1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1
InChI key
HZFGMQJYAFHESD-UHFFFAOYSA-M
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
faintly yellow to dark yellow
solubility
H2O: ≥5 mg/mL
storage temp.
2-8°C
Quality Level
Gene Information
human ... PTGS1(5742), PTGS2(5743)
Application
Bromfenac sodium has been used:
- to study its ability to bind to melanin
- in the synthesis of bromfenac indolinone standard
- to analyze its permeability in porcine conjunctiva
Biochem/physiol Actions
Bromfenac exhibits antipyretic and prostaglandin synthetase inhibiting properties. It has therapeutic properties against the reduction of ocular pain and inflammation in postoperative cataract patients. Bromfenac acts as an effective agent against allergic conjunctivitis. It has the potential to treat acute muscle pain, osteoarthritis, and rheumatoid arthritis.
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID) that inhibits both COX1 and COX2. It is used as an opthalmic analgesic.
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID); COX1 and COX2 inhibitor; opthalmic analgesic.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
저장 등급
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Christina Flaxel et al.
Retina (Philadelphia, Pa.), 32(3), 417-423 (2011-08-25)
To evaluate whether bromfenac eyedrops and ranibizumab intravitreal injections would provide added efficacy over ranibizumab alone. This was a single-site, multiinvestigator, prospective, open-label, interventional, Phase II study of patients with new or recurrent exudative/neovascular age-related macular degeneration. Thirty eyes were
Jeffrey S Heier et al.
Retina (Philadelphia, Pa.), 29(9), 1310-1313 (2009-11-26)
To assess vitreous concentrations of nonsteroidal antiinflammatory drugs (NSAIDs) and prostaglandin E(2) in patients treated with NSAIDs before vitrectomy. This was an investigator-masked, randomized, multicenter study. Patients received ketorolac 0.4% 4 times a day, bromfenac 0.09% 2 times a day
Frank A Bucci et al.
Advances in therapy, 28(12), 1089-1095 (2011-11-23)
We compared the prostaglandin E(2) (PGE(2)) inhibition of three topical nonsteroidal antiinflammatory drugs (NSAIDs): ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% at peak dosing levels in patients previously scheduled to undergo phacoemulsification. This was a single-center, double-masked observational study of
Frank A Bucci et al.
Current medical research and opinion, 27(12), 2235-2239 (2011-10-14)
To compare the peak to-aqueous penetration of three nonsteroidal anti-inflammatory drugs: ketorolac tromethamine 0.45%, bromfenac 0.09%, nepafenac 0.1%, and amfenac (the active metabolite of nepafenac) in patients undergoing phacoemulsification. A single center, double-masked study randomized 122 patients to receive one
Koichiro Mukai et al.
Journal of cataract and refractive surgery, 35(9), 1614-1618 (2009-08-18)
To evaluate the efficacy of ophthalmic nonsteroidal and steroidal antiinflammatory drugs in preventing anterior capsule contraction and secondary posterior capsule opacification (PCO) using an experimental cataract model. Department of Ophthalmology, Dokkyo Medical University, Tochigi, Japan. Eight-week-old albino rabbits weighing about
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.